サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1521205

オンコロジーベースIn-Vivo CRO市場レポート：適応症、モデル、用途、地域別、2024年～2032年

Oncology Based In-Vivo CRO Market Report by Indication (Blood Cancer, Solid Tumors, and Others), Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX), and Others), Application (Hospitals, Rehabilitation Centers), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 135 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=141.77円
オンコロジーベースIn-Vivo CRO市場レポート：適応症、モデル、用途、地域別、2024年～2032年
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のオンコロジーベースIn-Vivo CRO市場規模は2023年に12億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて6.9%の成長率（CAGR）を示し、2032年までに市場は23億米ドルに達すると予測しています。

腫瘍学は、生検、内視鏡検査、X線検査、コンピュータ断層撮影（CT）スキャン、磁気共鳴画像（MRI）スキャン、陽電子放射断層撮影（PET）スキャン、超音波検査などを用いてがんを研究、診断、治療する医学の一分野を指します。ホルモン療法、免疫療法、放射線療法、経口療法を患者に提供し、がんの副作用に耐え、緩和させる。現在、がん治療のためのCRO（医薬品開発業務受託機関）による複数の治験薬の研究開発により、オンコロジーベースIn-Vivo CROの需要が世界中で増加しています。

オンコロジーベースIn-Vivo CRO市場動向：

世界のがん罹患率の増加は、市場を牽引する重要な要因のひとつです。さらに、世界各国の政府は研究開発（R&D）活動に大規模な投資を行っています。これに加え、医薬品開発業務受託機関（CRO）によるがん治療に関する専門知識の向上が、市場の成長を後押ししています。さらに、デオキシリボ核酸（DNA）を操作して生物の特性を変化させる遺伝子工学の技術革新も増加しています。これは、細胞の増殖、成長、分化を制御するためのがん遺伝子研究への注目の高まりと相まって、市場にプラスの影響を与えています。これに加えて、医薬品の幅広い入手可能性とヘルスケア産業の拡大が、腫瘍学に基づくin-vivo CROの需要を世界的に刺激しています。これとは別に、受託研究機関（CRO）が自社調査と比較して提供するコスト効率は、業界の投資家に有利な成長機会を提供しています。さらに、ヘルスケア業界では、がん患者の安全性を確保するために遠隔医療やバーチャル臨床試験の採用が増加しています。これは市場の成長を後押しすると予測されます。

本レポートで扱う主な質問

  • 2023年における世界のオンコロジーベースIn-Vivo CRO市場の市場規模は？
  • 2024-2032年における世界のオンコロジーベースIn-Vivo CRO市場の予想成長率は？
  • 世界のオンコロジーベースIn-Vivo CRO市場を牽引する主要因は？
  • 世界のオンコロジーベースIn-Vivo CRO市場に対するCOVID-19の影響は？
  • 世界のオンコロジーベースIn-Vivo CRO市場の適応症別の内訳は？
  • 世界のオンコロジーベースIn-Vivo CRO市場の主要地域は？
  • 世界のオンコロジーベースIn-Vivo CRO市場の主要プレーヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のオンコロジーベースIn-Vivo CRO市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：適応症別

  • 血液がん
    • 市場動向
    • 市場予測
  • 固形腫瘍
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：モデル別

  • 同系
    • 市場動向
    • 市場予測
  • 異種移植
    • 市場動向
    • 市場予測
  • 患者由来異種移植（PDX）
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • 病院
    • 市場動向
    • 市場予測
  • リハビリテーションセンター
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Champions Oncology Inc.
    • Charles River Laboratories International Inc.
    • Crown Bioscience Inc.
    • Eurofins Scientific
    • Evotec SE
    • ICON Plc
    • Labcorp Drug Development（Laboratory Corporation of America Holdings）
    • Living Tumor Laboratory
    • Taconic Biosciences Inc.
    • The Jackson Laboratory
    • WuXi AppTec
    • Xentech
図表

List of Figures

  • Figure 1: Global: Oncology Based In-Vivo CRO Market: Major Drivers and Challenges
  • Figure 2: Global: Oncology Based In-Vivo CRO Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Oncology Based In-Vivo CRO Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Oncology Based In-Vivo CRO Market: Breakup by Model (in %), 2023
  • Figure 6: Global: Oncology Based In-Vivo CRO Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Oncology Based In-Vivo CRO Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Oncology Based In-Vivo CRO (Blood Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Oncology Based In-Vivo CRO (Blood Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Oncology Based In-Vivo CRO (Solid Tumors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Oncology Based In-Vivo CRO (Solid Tumors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Oncology Based In-Vivo CRO (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Oncology Based In-Vivo CRO (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Oncology Based In-Vivo CRO (Syngeneic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Oncology Based In-Vivo CRO (Syngeneic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Oncology Based In-Vivo CRO (Xenograft) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Oncology Based In-Vivo CRO (Xenograft) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Oncology Based In-Vivo CRO (Patient Derived Xenograft (PDX)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Oncology Based In-Vivo CRO (Patient Derived Xenograft (PDX)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Oncology Based In-Vivo CRO (Other Models) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Oncology Based In-Vivo CRO (Other Models) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Oncology Based In-Vivo CRO (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Oncology Based In-Vivo CRO (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Oncology Based In-Vivo CRO (Rehabilitation Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Oncology Based In-Vivo CRO (Rehabilitation Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Oncology Based In-Vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Oncology Based In-Vivo CRO Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Oncology Based In-Vivo CRO Industry: SWOT Analysis
  • Figure 76: Global: Oncology Based In-Vivo CRO Industry: Value Chain Analysis
  • Figure 77: Global: Oncology Based In-Vivo CRO Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Oncology Based In-Vivo CRO Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Model (in Million US$), 2024-2032
  • Table 4: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Oncology Based In-Vivo CRO Market: Competitive Structure
  • Table 7: Global: Oncology Based In-Vivo CRO Market: Key Players
目次
Product Code: SR112024A5438

The global oncology based in-vivo CRO market size reached US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032.

Oncology refers to a branch of medicine that studies, diagnoses, and treats cancer using biopsy, endoscopy, X-ray, computed tomography (CT) scanning, magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, and ultrasound. It offers hormonal therapy, immunotherapy, radiotherapy, and oral therapies to patients for tolerating and easing the side effects of cancer. At present, there is a rise in the demand for oncology based in-vivo CRO across the globe due to the development of several investigational compounds by contract research organizations (CROs) for treating cancer.

Oncology Based In-Vivo CRO Market Trends:

The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities. This, along with the rising expertise in cancer treatment by contract research organizations (CROs), is propelling the growth of the market. In addition, there is an increase in the innovation of genetic engineering for manipulating deoxyribonucleic acid (DNA) and altering the characteristics of organisms. This, coupled with the growing focus on oncogene study to regulate proliferation, growth, and differentiation of cells, is positively influencing the market. Besides this, the wide availability of medicines, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Apart from this, the cost-efficiency offered by contract research organizations (CROs) compared to an in-house study is offering lucrative growth opportunities to industry investors. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry for ensuring the safety of cancer patients. This is projected to bolster the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology based in-vivo CRO market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication, model and application.

Breakup by Indication:

Blood Cancer

Solid Tumors

Others

Breakup by Model:

Syngeneic

Xenograft

Patient Derived Xenograft (PDX)

Others

Breakup by Application:

Hospitals

Rehabilitation Centers

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec and Xentech.

Key Questions Answered in This Report

  • 1. What was the size of the global oncology based in-vivo CRO market in 2023?
  • 2. What is the expected growth rate of the global oncology based in-vivo CRO market during 2024-2032?
  • 3. What are the key factors driving the global oncology based in-vivo CRO market?
  • 4. What has been the impact of COVID-19 on the global oncology based in-vivo CRO market?
  • 5. What is the breakup of the global oncology based in-vivo CRO market based on the indication?
  • 6. What is the breakup of the global oncology based in-vivo CRO market based on the model?
  • 7. What are the key regions in the global oncology based in-vivo CRO market?
  • 8. Who are the key players/companies in the global oncology based in-vivo CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oncology Based In-Vivo CRO Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Blood Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Solid Tumors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Model

  • 7.1 Syngeneic
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Xenograft
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Patient Derived Xenograft (PDX)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Rehabilitation Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Champions Oncology Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Charles River Laboratories International Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Crown Bioscience Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Eurofins Scientific
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Evotec SE
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 ICON Plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Labcorp Drug Development (Laboratory Corporation of America Holdings)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 Living Tumor Laboratory
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Taconic Biosciences Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 The Jackson Laboratory
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 WuXi AppTec
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 Xentech
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio